Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
Open Access
- 27 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 10 (6) , 488-499
Abstract
Aims: Icosapent ethyl lowers triglycerides and significantly reduces major adverse cardiovascular events (MACE), though treatment effects may vary between individuals. This study aimed to determine the relative and absolute effects of icosapent ethyl on MACE according to baseline cardiovascular disease (CVD) risk in patients with atherosclerotic cardiovascular disease (ASCVD). Methods and Results: Participants from the Reduction of Cardiovascular Events with Icosapent Ethyl—Intervention Trial (REDUCE-IT) with ASCVD were included (n = 5785). The primary outcome was 3-point MACE, i.e. non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. Baseline 5-year risk of MACE was estimated using the European Society of Cardiology (ESC) guideline-recommended SMART2 risk score. Modification of the relative treatment effects of icosapent ethyl by baseline risk was assessed using Cox proportional hazards models, including a treatment-by-risk interaction. Next, treatment effects were assessed stratified by quartiles of baseline risk. During a median follow-up of 4.8 years (interquartile range 3.2–5.3), MACE occurred in 361 vs. 489 patients in the icosapent ethyl vs. placebo group [95% confidence interval (CI)]; hazard ratio (HR) 0.72 (0.63–0.82), absolute risk reduction (ARR) 4.4% (2.6–6.2%), number needed to treat (NNT) 23 (16–38), and 5-year Kaplan-Meier estimated cumulative incidence reduction (CIR) 5.7% (3.5–7.9%). Icosapent ethyl significantly reduced MACE in all risk quartiles, with an HR (95% CI) of 0.62 (0.43–0.88), 0.66 (0.48–0.92), 0.69 (0.53–0.90), and 0.78 (0.63–0.96), respectively (P for treatment-by-risk interaction = 0.106). The ARR (95% CI) increased across risk quartiles, i.e. was 3.9% (1.0–6.8%), 4.3% (1.2–7.3%), 5.1% (1.4–8.7%), and 5.6% (1.3–10.0%), respectively. This translates to NNTs (95% CI) of 26 (15–98), 24 (14–84), 20 (11–70), and 18 (10–77). The 5-year CIR (95% CI) was 4.8% (1.3–8.2%), 5.0% (1.3–8.7%), 6.1% (1.7–10.5%), and 7.7% (2.3–13.2%), respectively. Consistent results were obtained for 5-point MACE, additionally including coronary revascularization and unstable angina. Conclusion: Among patients with ASCVD and elevated triglyceride levels, icosapent ethyl significantly reduces the risk of MACE irrespective of baseline CVD risk, though absolute benefits are largest for patients at the highest risk.Keywords
Funding Information
- Amarin Pharma
This publication has 32 references indexed in Scilit:
- Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionJACC, 2022
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent HypertriglyceridemiaJACC, 2021
- Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event RiskJACC, 2020
- Effects of Icosapent Ethyl on Total Ischemic EventsJACC, 2019
- Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention TrialClinical Cardiology, 2017
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic InterventionsJAMA, 2016
- Moving Toward Global Primordial Prevention in Cardiovascular DiseaseJACC, 2015
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart DiseaseJACC, 2012
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With AtherothrombosisJAMA, 2010
- Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical TrialsJAMA, 1991